OV-90细胞

OV-90/OV-90细胞系/OV-90细胞株/OV-90人卵巢癌贴壁细胞

Cell line name OV-90

Synonyms OV90

Accession CVCL_3768

Resource Identification Initiative To cite this cell line use: OV-90 (RRID:CVCL_3768)

Comments Group: Patented cell line.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: OCCP ovarian cancer cell line panel.

Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11732.

Population: Caucasian.

Doubling time: 1.5 days (PubMed=10949993); 40 hours (PubMed=25984343); 46.34 hours (JWGray panel).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Misspelling: TOV-90; Cosmic=1139219.

Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.

Sequence variations

Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (PubMed=24675677).

Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (DepMap=ACH-000291).

Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (PubMed=10949993; PubMed=20204287; PubMed=24023729; PubMed=25230021; PubMed=28273451; DepMap=ACH-000291).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*02:05,02:05

HLA-B B*15:05,50:01

HLA-C C*06:02,07:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 2.24

Native American 0

East Asian, North 2.36

East Asian, South 0

South Asian 5.06

European, North 37.26

European, South 53.08

Disease Ovarian adenocarcinoma (NCIt: C7700)

Adenocarcinoma of ovary (ORDO: Orphanet_213504)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_4Z23 (OV90C-A) CVCL_4Z24 (OV90C-D) CVCL_4Z25 (OV90D-6)

CVCL_4Z26 (OV90D-7) CVCL_4Z27 (OV90P-3) CVCL_4Z28 (OV90P-7)

Sex of cell Female

Age at sampling 64Y

Category Cancer cell line

STR profile Source(s): ATCC=CRL-3585; Cosmic-CLP=1240197; Direct_author_submission; PubMed=25230021; PubMed=25877200; PubMed=30485824

 

Markers:

Amelogenin X

CSF1PO 12,13

D3S1358 18

D5S818 11,15

D7S820 10 (Cosmic-CLP=1240197; Direct_author_submission)

10,10.1 (ATCC=CRL-3585; PubMed=25230021; PubMed=25877200)

10.1 (PubMed=30485824)

D8S1179 12,14

D13S317 11,12

D16S539 11

D18S51 12

D21S11 30,30.2

FGA 21,22

Penta D 12,13

Penta E 11,13

TH01 9.3

TPOX 8,10

vWA 16,17

 

Run an STR similarity search on this cell line

Publications

Patent=US5710038

Mes-Masson A.-M., Provencher D.M.

Primary cultures of normal and tumoral human ovarian epithelium.

Patent number US5710038, 20-Jan-1998

 

PubMed=10949993; DOI=10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2

Provencher D.M., Lounis H., Champoux L., Tetrault M., Manderson E.N., Wang J.-C., Eydoux P., Savoie R., Tonin P.N., Mes-Masson A.-M.

Characterization of four novel epithelial ovarian cancer cell lines.

In Vitro Cell. Dev. Biol. Anim. 36:357-361(2000)

 

PubMed=11641787; DOI=10.1038/sj.onc.1204804

Tonin P.N., Hudson T.J., Rodier F., Bossolasco M., Lee P.D., Novak J., Manderson E.N., Provencher D.M., Mes-Masson A.-M.

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.

Oncogene 20:6617-6626(2001)

 

PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445

Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Oncol. Rep. 23:1021-1026(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22141344; DOI=10.1186/1757-2215-4-21; PMCID=PMC3259089

Sherman-Baust C.A., Becker K.G., Wood W.H. 3rd, Zhang Y.-Q., Morin P.J.

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin.

J. Ovarian Res. 4:21.1-21.11(2011)

 

PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170; PMCID=PMC3274821

Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.

Genomic complexity and AKT dependence in serous ovarian cancer.

Cancer Discov. 2:56-67(2012)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396

Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Cancer Discov. 2:172-189(2012)

 

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677

Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Gynecol. Oncol. 127:241-248(2012)